Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
Ratings has upgraded the issuer rating and senior unsecured notes ratings of global pharmaceutical company Eli Lilly and ...
The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...
Plus: A constellation of data-gathering balloons, an asteroid may strike the Earth next decade and how to perfectly boil an ...
However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback